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Eﬀects of a topical cream containing P. amboinicus (Lour.) Spreng. (Lamiaceae) and C. asiatica (L.) Urban (Umbelliferae) were
evaluated and compared to eﬀects of hydrocolloid ﬁber wound dressing for diabetic foot ulcers. A single-center, randomized,
controlled, open-label study was conducted. Twenty-four type 1 or type 2 diabetes patients aged 20 years or older with Wagner
grade 3 foot ulcers postsurgical debridement were enrolled between October 2008 and December 2009. Twelve randomly assigned
patients were treated with WH-1 cream containing P. amboinicus and C. asiatica twice daily for two weeks. Another 12 patients
were treated with hydrocolloid ﬁber dressings changed at 7 days or when clinically indicated. Wound condition and safety were
assessed at days 7 and 14 and results were compared between groups. No statistically signiﬁcant diﬀerences were seen in percent
changesinwoundsizeat7-and14-dayassessmentsofWH-1creamandhydrocolloiddressinggroups.Aslightlyhigherproportion
of patients in the WH-1 cream group (10 of 12; 90.9%) showed Wagner grade improvement compared to the hydrocolloid ﬁber
dressing group but without statistical signiﬁcance. For treating diabetic foot ulcers, P. amboinicus and C. asiatica cream is a safe
alternative to hydrocolloid ﬁber dressing without signiﬁcant diﬀerence in eﬀectiveness.
1.Introduction
Development of foot ulcers is a common complication of
diabetes. Approximately 15% to 20% of 16 million people
with diabetes in the United States are hospitalized for
foot ulceration and subsequent infection during the disease
course [1]. Foot ulcers are primarily caused by peripheral
neuropathy that reduces protective sensations for pain and
temperature associated with trauma, and also by motor
neuropathies that result in foot deformity, local pressure,
and eventual ulceration [2]. A multicenter study identiﬁed
peripheral sensory neuropathy, trauma and deformity as
causative factors in 63% of diabetes patients; ischemia, callus
formation, and edema were other prominent factors in ulcer
etiology [3]. Infection often follows diabetic foot ulceration
duetovascularinsuﬃciencyandreducedleukocytefunction.
Diabetic foot infections range from simple cellulitis to
more complicated chronic osteomyelitis and are associated
with increased frequency of infection, high morbidity with
increased hospitalization, and lower extremity amputation
[1, 4]. In diabetes patients, mild, moderate, and severe foot
infectionsareallconsideredseriousbecausethecombination
o fa no p e nw o u n da n dr e d u c e di m m u n ed e f e n s e sm a y
quickly spread infection into the subcutaneous tissue and
deeper structures [5]. Impaired microvascular circulation
characteristic of diabetes limits transport of phagocytic cells
and antibiotics to the aﬀected area, predisposing diabetes
patients to more frequent and potentially more severe foot
lesions that are more diﬃcult to treat. Treatment of foot
ulcers and resultant infection may involve aggressive surgical
debridement [4], oral or intravenous antibiotics [6, 7], and
wound management with topical applications [8]. Metabolic
abnormalities also require correction if foot ulcer treatment
c a nb ee x p e c t e dt ob ee ﬀective [2].
Prompt, eﬀective treatment of foot ulcers is essential
to reduce risk of exacerbation and amputation. Wound2 Evidence-Based Complementary and Alternative Medicine
closure is the main treatment goal and the type of treatment
employed depends on wound severity, vascularity, and
whether infection is present. Treatment may include foot
elevation, pressure relief, debridement of necrotic tissue,
and application of various topical treatments, including wet-
to-dry dressings, topical antiseptics, semipermeable ﬁlms,
foams, hydrocolloids, and calcium alginate swabs, among
others [1]. Botanical and herbal treatments have been used
for centuries in traditional Chinese medicine (TCM) as
evidenced by recent reports of TCM drug use patterns
in a general hospital in Taiwan [9]. We formulated an
investigational botanical product designated as WH-1 cream
for the treatment of diabetic foot ulcers. WH-1 cream con-
tains extracts from two botanical raw materials, Plectranthus
amboinicus (Lour) Spreng (Lamiaceae) and Centella asiatica
(Linn) Urban (Umbelliferae). P. amboinicus and C. asiatica
have exhibited anti-inﬂammatory and healing properties
applicable to wound treatment. P. amboinicus is one of
nearly 300 botanical species in the Plectranthus genus of the
Lamiaceae family, which is noted for its diversity of use, par-
ticularly as medicines for skin, infective, digestive, and res-
piratory problems [10]. In its native environment in Kenya,
Africa, it is the most frequent Plectranthus species applied to
treat burns, wounds, sores, insect bites, and skin allergies.
Evaluation of the in vivo (rat model) anti-inﬂammatory
and antitumor activities of an extract from the leaves of P.
amboinicus results showed signiﬁcant reduction of edema
and conﬁrmed the anti-inﬂammatory properties at speciﬁc
dosage levels [11]. In Taiwan and other East and South
Asian countries, where Plectranthus species have been used
for treating cough, fever, sore throat, mumps, and mosquito
bites, Chiu et al. [12] investigated the anti-inﬂammatory and
analgesic properties of P. amboinicus extract in vivo and in
vitro. The extract inhibited pain induced in mice by acetic
acid and formalin injection and inﬂammation induced by
carrageenan. The anti-inﬂammatory eﬀect was attributed
to modulating antioxidant enzyme activity in the liver and
production of tumor necrosis factor alpha (TNF-α). Shukla
etal.[13]isolatedasiaticosidefromC.asiaticaandfoundthat
hydroxyproline increased 56%, tensile strength increased
57% and both collagen and epithelialization increased after
topical application of 0.2% asiaticoside solution to punch
wounds in guinea pigs. The active constituents of C.
asiatica include pentacyclic triterpene derivatives shown to
be eﬀective in treating venous insuﬃciency and striae gravi-
darum (pregnancy-related stretch marks) [14]. Its sedative,
analgesic, antimicrobial, antiviral, and immunomodulatory
eﬀects have also been studied but without conﬁrmation of
speciﬁc eﬀects.
To investigate the eﬀectiveness of WH-1, we compared
its eﬀects to a relatively new hydrocolloid ﬁber dressing with
demonstrated eﬀectiveness (Aquacel Hydroﬁber Dressing,
ConvaTec, Valencia, CA, USA). This occlusive, adhesive
dressing combines absorbent carboxy-methyl-cellulose non-
woven ﬁber to manage partial- and full-thickness wounds.
It is reported to absorb up to three times its weight in
exudate while providing an optimum healing environment
andminimalbacterialcross-contamination[15].Althoughit
is one of the standard treatments applied by plastic surgeons,
healing time results have varied [15–17].
While botanical and herbal therapies are usually applied
safely and eﬀectively, severe adverse eﬀects of these agents
have been reported when used either directly or combined
with standard Western medical approaches [18, 19]. There-
fore, such treatments must be subjected to scientiﬁc study
to support their continued use by demonstrated safety and
eﬃcacy. This study aimed to evaluate the eﬀe c t so fat o p i c a l
cream containing P. amboinicus and C. asiatica compared
to the eﬀects of hydrocolloid ﬁber wound dressing when
applied topically to diabetic foot ulcers in patients with
diabetes type 1 and type 2.
2.MaterialsandMethods
A single-center, randomized, controlled, open-label study
was conducted between October 2008 and December 2009.
2.1. Subjects. Twenty-four type 1 or type 2 diabetes patients
aged 20 years and older with Wagner grade 3 foot ulcers
postsurgical debridement were enrolled. Wagner grade 3
was deﬁned as “deep ulcer involving osteitis, abscess, or
osteomyelitis” according to the Wagner classiﬁcation system
[20].
Inclusion criteria were patients with type 1 or type
2 diabetes, aged 20 years or older, and having Wagner
grade 3 foot ulcers postsurgical debridement. Patients with
poor nutritional status (albumin <3g/dL), poor diabetic
control (HbA1c >10%), anemia (hemoglobin <10g/dL),
and leukocyte counts <1,000/cu mm were excluded. Other
exclusion criteria were presence of connective tissue disease
or known or suspected malignancy local to the study ulcer;
renal failure insuﬃciency (serum creatinine >1.5mg/dL) or
abnormal liver function (AST, ALT >2.5 × upper limit of
normal range); requiring treatment with immunosuppres-
sive agents, corticosteroids, chemotherapy or radiotherapy;
female patients with positive pregnancy test or breastfeeding
or unwilling to use appropriate contraceptive methods
during study; patients with known sensitivity to essential oils
or lanolin cream. Withdrawal criteria included withdrawal
of consent, lost to follow up, treatment failure (deﬁned as
worsening of Wagner grade or serious infection in ulcer
site), and requiring the use of a prohibited medication.
Withdrawal was also a consideration if any other medical
condition was present that, in the opinion of the principal
investigator, indicated that continued treatment with study
therapy and participation in this trial was not in the best
interest of the patient. The 24 patients were randomly
assigned to two equal groups comprising 12 patients in a
WH-1 cream group treated with WH-1 cream containing
P. amboinicus and C. asiatica twice daily for two weeks and
another 12 patients in a hydrocolloid group treated with
hydrocolloid ﬁber dressings during the same time period.
2.2. Ethical Considerations. All enrolled patients were ad-
vised about their participation in the study and all provided
signed informed consent. The study protocol was reviewedEvidence-Based Complementary and Alternative Medicine 3
and approved by the Institutional Review Board (IRB) of
NationalTaiwanUniversityHospital(IRBno.200801067M).
2.3. Formulation of Investigational Product: WH-1 Cream.
WH-1 cream contained extracts from two botanical raw
materials, P. amboinicus and C. asiatica. The plants of
P. amboinicus were collected on 2007 according to good
agricultural and good collection practices. C. asiatica.e x tra ct
was sourced commercially with certiﬁcate of analysis of the
extract and herbal material. Guided by previous pharma-
cological wound healing studies [11–14], the most active
fractions, PA-F4 from P. amboinicus and S1 from C. asiatica,
were combined in a 1:4 ratio to form the drug substance
WH1-DS. The ﬁnal drug product, WH-1 cream, contained
1.25% of drug substance in a cream base, 15g per tube.
The cream base contained cetostearyl alcohol, ireine, liquid
petrolatum, methyl paraben propyl paraben, Span 60, Tween
60, white petrolatum, water, and pigments.
2.4. Treatment Administration. During the two-week study
period, WH-1 cream was applied topically twice daily to 12
WH-1 group patients in an amount to fully cover the ulcer
area in a thin and even layer. The maximum amount must
not exceed 2 millimeters in thickness. After each application,
the comparative product, hydrocolloid ﬁber wound dressing
(AQUACEL Hydroﬁber Dressing) was applied to 12 patients
in the hydrocolloid ﬁber dressing group and left in place for
up to 7 days or changed earlier as clinically indicated. After
applying WH-1 cream or hydrocolloid ﬁber dressing, the
wound was covered with a transparent, adhesive, waterproof
dressing (Opsite, Smith & Nephew, Taipei, Taiwan). After
wound dressing for two weeks, the wounds in both groups
wereallreconstructedbysplit-thicknessskingraftorprimary
closure.
Treatment allocation was performed before site initia-
tion.Permuted-blocktreatmentallocationwasusedtoassign
participants to each group. A list of sequential numbers was
generated using a permuted-block randomization procedure
withablocksizeof4inSAS9.1,witheachnumberrandomly
assigned to one group. Patients meeting the inclusion and
exclusion criteria were randomly assigned in a 1:1 ratio to
the WH-1 cream group or the hydrocolloid ﬁber dressing
group according to a predeﬁned randomization schedule.
After random assignment, subjects received the study med-
ication at the baseline visit and were assessed for wound
condition and safety during the 2-week treatment period
(follow-up visits at the 7th and 14th day). Hydrocolloid
ﬁber dressing group patients had the dressing applied at
baseline and changed at the 7th day or earlier if clinically
indicated.
2.5. Wound Assessment. Prior to beginning the study, all
patients in both treatment groups had received surgical
debridement with complete reduction of necrotic tissue
and debris to visualization of bleeding healthy tissue. After
the study treatment period, the primary endpoint was the
percentage change in wound size deﬁned as wound size at
endpoint (days7and14) comparedtowoundsizeatbaseline
(postsurgicaldebridement).Thesecondaryendpointwasthe
improvement in Wagner Grade from baseline (all patients
were Wagner grade 3 at baseline postdebridement) to ﬁnal
visit at day 14. Safety assessment involved the observation of
presence or absence of adverse events for the study period.
Laboratory parameters measured included: hemoglobin,
HbA1c, WBC with diﬀerential counts, AST, ALT, albumin,
creatinine, fasting plasma glucose, BUN, and urine protein,
which were tested at screening/baseline and at the end of
study (day 14). A pregnancy test was indicated for females
of child-bearing potential before the study began.
Physical examination and vital signs were done at
baseline and at days 7 and 14. Concomitant treatments were
permitted as follows: sharp surgical debridement (including
resection of necrotic soft tissue and bone, sinus tracts,
ﬁstulae, undermined borders, callus) to form viable wound
margins was performed before randomization and repeated
as needed during the dosing period. Systemic antimicrobial
agents were allowed for treatment of infections. Non-
weight bearing or oﬄoading was required for all subjects.
Prohibited treatments during the study period included
immunosuppressive agents, corticosteroids, chemotherapy
and radiotherapy.
2.6. Statistical Analysis. Demographic parameters and other
baseline characteristics were analyzed by treatment group
for the randomized population. The intent-to-treat (ITT)
population contained all randomized patients who had
receivedatleastonedoseofstudymedicationandhadatleast
one follow-up eﬃcacy endpoint evaluation. Additionally,
only patients with a Wagner grade 3 foot ulcer were included
in the ITT population. Analysis of primary and secondary
endpoints was based on the ITT population. The safety
population was deﬁned as all randomized patients who had
taken any dose of study medications and was the primary
population for analyzing the safety data.
Comparability among the two treatment groups was
evaluated using Mann-Whitney U test for continuous vari-
ables and Fisher’s exact test for categorical variables. Data are
presented as a median (interquartile range) for continuous
data and numbers (percentages) for categorical data. The
Wilcoxon signed ranks test was used to compare diﬀerences
before and after treatment in each group. All statistical
assessments were two-sided and evaluated at the 0.05 level
of signiﬁcant diﬀerence. Statistical analyses were performed
using SPSS 15.0 statistics software (SPSS Inc., Chicago, IL,
USA) and SAS 9.1 (SAS Institute Inc., Cary, NC, USA).
3. Results
A total of 24 patients were screened and enrolled into
the study between October 29, 2008 and December 14,
2010. Of these, 12 patients were randomly assigned to the
WH-1 cream group and 12 patients to the hydrocolloid
ﬁber dressing group. No participants were excluded during
screening. Figure 1 shows a ﬂow chart of the trial that
presents the reasons for early termination and protocol
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Aquacel Hydroﬁber dressing group
(n = 12)
Figure 1: Patients’ ﬂow chart.




Hydroﬁber dressing (n = 12) P value
Age (years)1 75.5 (50.0, 82.0) 69.5 (59.0, 79.5) 0.862
Gender, n (%)2 1.000
Male 4 (33.3) 5 (41.7)
Female 8 (66.7) 7 (58.3)
Target side, n (%)2
Right 5 (41.7) 6
Left 7 (58.3) 6
Height (cm)1 160 (144, 166) 160 (151, 168) 0.758
Weight (kg)1 64 (50, 101) 67 (63, 77) 0.758
BMI (kg/m2)1 30.82 (24.01, 36.68) 25.04 (22.97, 30.68) 0.356
Wound size (cm2)1 3.92 (1.18, 10.64) 4.47 (2.57, 14.57) 0.386
P values are from 1Mann-Whitney U test and 2Fisher’s exact test.
Values are 1median (interquartile) and 2number (percentage).
ﬁber dressing group did not complete the study because
the patient withdrew consent and decided to receive full-
thickness skin grafts. Two other patients (1 in WH-1 group
and 1 in hydrocolloid ﬁber dressing group) were protocol
violating because their ulcers were not Wagner grade 3 at
enrollment.
WH-1 cream group patients included 4 men and 8
women with a median age of 75.5 years (range, 36–87 years)
and the hydrocolloid ﬁber dressing group included 5 men
and 7 women with a median age of 69.5 years (range,
44–89 years). No statistically signiﬁcant diﬀerences were
foundbetweenthetwogroupsinpatients’demographicsand
baseline characteristics (P>0.05) (Table 1).
The ITT population comprised 21 patients; 11 patients
treated with WH-1 and 10 patients treated with hydrocolloid
ﬁber dressing. The primary endpoint, percent changes in
wound size from baseline at the ﬁnal visit (day 14, end week
2)intheITTpopulationareshowninTable 2.Nostatistically
signiﬁcant diﬀerences were found in the percent changes
in wound size between the WH-1 cream and hydrocolloid
ﬁber dressing groups (P = 0.673). Analysis of results within
treatment groups showed that only the hydrocolloid ﬁber
dressing group had signiﬁcant decreases in wound sizes from
baseline to the ﬁnal visit (P = 0.037, Figure 2).
After 2 weeks of treatment, 4 (36.4%) patients had
Wagner grades 2 and 6 (54.6%) patients had Wagner gradeEvidence-Based Complementary and Alternative Medicine 5








Percent changes in wound size (%)1 −27.18 (−38.86, 36.10) −22.64 (−36.90, −3.20) 0.673
Secondary endpoint
Improvement on Wagner Grade, n (%)2 10 (90.9) 7 (70.0) 0.311
P values are from 1Mann-Whitney U test and 2Fisher’s exact test.
Values are 1median (interquartile) and 2number (percentage).
Figure 2: Changes of wound size.
1 in the WH-1 cream group; 4 (40.0%) patients had Wagner
grade 2 and 3 (30.0%) patients had Wagner grade 1 in the
hydrocolloid ﬁber dressing group. The secondary endpoint
was the proportion of patients who had improvements in
Wagner grade, and improvement in the WH-1 group (10
of 11 patients, 90.9%) was slightly higher than that in
the hydrocolloid ﬁber dressing group (7 of 10 patients,
70.0%), but the diﬀerence was not statistically signiﬁcant
(P = 0.311). Figure 3 shows photographs demonstrating
improvements in wound size and Wagner grades of the WH-
1c r e a mg r o u p .
All adverse events (AEs) were collected by patients or
monitored by the investigator throughout the study and
were coded using the 13th quarter Medical Dictionary for
Regulatory Activities (MedDRA version 13.1). The numbers
(%) of patients with at least one adverse event of maximum
severity during the treatment period are summarized in
Table 3. During the treatment period, 5 of 12 patients in
the WH-1 cream group (41.7%) and 5 of 12 patients in the
hydrocolloid ﬁber dressing group (41.7%) reported at least
one adverse event. According to the investigator’s judgment,
none of these events was study treatment related. No
signiﬁcant diﬀerence in adverse events was found between
the WH-1 cream and hydrocolloid ﬁber dressing groups
(P>0.05). In addition, there was no death or serious adverse
events in any patient during this clinical study.
4. Discussion
In this study, we compared the eﬀe c t so fab o t a n i c a l
cream containing P. amboinicus and C. asiatica with the
eﬀects of hydrocolloid ﬁber wound dressing when applied
topically to diabetic foot ulcers. No statistically signiﬁcant
diﬀerences were found in the percent changes in wound size
and improvements in Wagner grade between two groups
of diabetes patients who were treated with either WH-
1 cream or hydrocolloid ﬁber dressings for the two-week
study period. Although the proportion of patients who
showed improvement in Wagner grade was slightly higher in
patients treated with WH-1 cream than in those treated with6 Evidence-Based Complementary and Alternative Medicine
Wound size: 4.58 cm2, Wagner grade 3
Wound size: 11.27 cm2, Wagner grade 3
Wound size: 23.52 cm2, Wagner grade 3
(a)
Wound size: 2.8 cm2, Wagner grade 1
Wound size: 8.06 cm2, Wagner grade 2
Wound size: 17.13 cm2, Wagner grade 2
(b)
Figure 3:TheimprovementinwoundsizeandWagnergradesofthreepatientsintheWH-1creamgroup.(a)BeforeWH-1creamtreatment,
(b) the 14th day after treatment.
hydrocolloid ﬁber dressing (90.9% versus 70%, resp.), the
diﬀerence was not signiﬁcant. However, within-group anal-
yses showed that only the hydrocolloid ﬁber dressing group
had signiﬁcant decreases in wound sizes from baseline to the
ﬁnal visit. Safety assessment was similar in both groups, with
only minimal adverse events and no serious adverse events
reported or observed during the study period. Also, no pro-
nouncedchangeswereseeninmeanSBP,DBP,pulserateand
body temperature in any patient. Few changes were noted in
clinical laboratory data (i.e., hematology, serum chemistries,
and urinalysis) and none were clinically signiﬁcant.
Taking Chinese herbs is a common self-treatment behav-
ior in Asian society as well as a frequently prescribed
treatment, especially for patients with major diseases [9]. It
is not unusual that we apply a botanical medicine to the
treatment of diabetic foot ulcers and achieve good results
without adverse events. However, reports of severe adverse
eﬀects induced by botanical or herbal agents directly or by
combined use with standard Western medicine are found in
the literature [18, 19]. Systemic absorption of those agents
remains problematic. In this study, results showed that the
systemic absorption of WH-1 cream was minimal and it
appeared to be safe and well tolerated when administered to
patients with diabetic foot ulcers. Our results provide helpful
evidence and insight into the use of extracts from Chinese
herbs for modern treatment applications.Evidence-Based Complementary and Alternative Medicine 7







Any adverse event(s) 5 (41.7%) 5 (41.7%) 1.000
Constipation 2 (16.7%) 3 (25.0%) 1.000
Tinea pedis 22 (16.7%) 0 (0.0%) 0.478
Hypoglycemia 1 (8.3%) 0 (0.0%) 1.000
Dizziness 1 (8.3%) 0 (0.0%) 1.000
Visual ﬁeld defect 1 (8.3%) 0 (0.0%) 1.000
Conjunctivitis 0 (0.0%) 1 (8.3%) 1.000
Diarrhoea 0 (0.0%) 1 (8.3%) 1.000
Gastritis 0 (0.0%) 1 (8.3%) 1.000
Vomiting 0 (0.0%) 1 (8.3%) 1.000
Oedema 0 (0.0%) 1 (8.3%) 1.000
P values are from Fisher’s exact test.
The insigniﬁcant diﬀerences between WH-1 and hydro-
colloid ﬁber dressing can be explained in part because
of the relatively short observation period in this prelim-
inary study. Most short-term studies showed preliminary
“healing” signals such as reepithelization, which can only
be conﬁrmed through advanced conﬁrmatory research. For
example, “Regranex” (becaplermin, the only FDA-approved
prescription platelet-derived growth factor gel for deep
neuropathic diabetic foot ulcers) demonstrated only a slight
improvement in ulcer volume (P = 0.056) when used in
41 patients in a 28-day dose-ranging phase II study [21].
However, Regranex was reported to have a 50% incidence
of complete wound closure in the pivotal 20-week phase
III study [22]. Other studies of topical applications for foot
ulcers have been longer but have not necessarily yielded
better results. For example, in a comparative study between
honey and povidone iodine applied as dressing solutions for
Wagner grade 2 diabetic foot ulcers, patients were followed
for 6 weeks and a mean healing time of 14.4 days (range
7 to 26 days) was achieved for patients receiving honey
treatment compared to 15.4 days (range 9–36 days) for
povidone iodine patients; even without signiﬁcant diﬀerence
in healing time, it could still be concluded that honey was
a safe alternative dressing for Wagner grade 2 foot ulcers
[23]. Another multicenter trial investigating three dressings
for managing diabetic foot ulcers had a duration of 12 weeks
and signiﬁcant diﬀerences were noted in results between the
three treatment groups but none directly related to mean
healing time [15]. Nevertheless, in future research expanding
our present preliminary study results, we will apply longer
continuous treatment and observation of diabetic foot
ulcers.
Another possible explanation for lack of signiﬁcant
diﬀerences between WH-1 cream and a topical cream with
a hydrocolloid preparation could be the comparison of
“apples and oranges.” However, the hydrocolloid wound
dressing used in our study (Aquacel Hydroﬁber Dressing)
was one of three dressings investigated in a large, multicenter
trial to determine whether modern dressings were more
clinically eﬀective than traditional dressings in the treatment
of diabetes-related foot ulcers [15]. In that “apples to apples”
comparison, no diﬀerences in eﬀectiveness were found in
the three dressings in terms of percentage healed at 24
weeks or in the mean time to healing or quality of healing
(i.e., incidence of recurrence). While that study compared
parallel treatments over a longer period of time, the only
signiﬁcance was that the hydrocolloid ﬁber dressing proved
to be signiﬁcantly more costly per treatment even though
fewer changes of dressing were required to achieve the
same results. This suggests that more information about the
eﬀectiveness of WH-1 could be gained through comparisons
with a wider range of topical medicines as well as newer
products in widespread use.
Further investigation of P. amboinicus and C. asiat-
ica cream must include other clinical parameters such
as pulsation, Doppler ultrasound, and patients’ subjective
symptoms. Also, in the present study, only wound sizes
and improvements in Wagner grades were compared and
other signs and symptoms associated with diabetic foot
ulcers, including pain, numbness, pallor, and pulses, were
not compared. We also did not focus on infection of foot
ulcers since our investigational product was not intended as
an antimicrobial measure; however, infection was noted and
recorded in some patients and systemic antimicrobial agents
were allowed for treatment of infections. When diabetic foot
ulcers of diﬀerent Wagner grades and infection by diﬀerent
organisms were investigated by culture and sensitivity and
susceptibility to citric acid as the sole antimicrobial agent,
citric acid gel was 94% eﬀective in controlling foot infections
for Wagner grades 1 and 2 and also in Wagner grade 3
without deep osteomyelitis [8]. One drawback of the Wagner
classiﬁcation system is that it does not factor in the presence
of infection [4]. Since infection may be another factor
in the insigniﬁcant results between the investigated WH-1
cream versus a highly absorbent hydrocolloid ﬁber dressing,
future studies may expand our approach to determine
possible relationships between infection, wound sizes, and
improvements in Wagner grade.8 Evidence-Based Complementary and Alternative Medicine
5. Limitations
This study has certain limitations, including that it is
a single-site study with a small sample and a short
observation period for wound reconstruction. It is
essentially a pilot study conducted to observe safety
and eﬀectiveness of the botanical cream designated as WH-1
in treating Wagner grade 3 foot ulcers since the investigated
product is currently undergoing a phase II clinical trial
for treatment of Wagner grade 1 diabetes foot ulcers
[http://clinicaltrials.gov/ct2/show/NCT00709514?term=wh1
&rank=1]. Future study will include comparisons with a
wider range of topical treatments for diabetic foot ulcers and
an expanded sample and longer study period.
6. Conclusion
Fortreatingdiabeticfootulcers,P.amboinicusandC.asiatica
cream is a safe alternative to hydrocolloid ﬁber wound
dressing without signiﬁcant diﬀerences in eﬀectiveness. P.
amboinicus and C. asiatica cream is a safe and eﬀective
alternative for use in patients for whom hydrocolloid ﬁber
wound dressing may be contraindicated.
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